Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DTYMK | P23919 | 1/20 | 0.42 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 11/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.37 |
| ▸ | FEN1 | P39748 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2176354 | 0.85 | L3MBTL1 (0.42) | DTYMKDDB1CRBNPOLBELANE | |
| SCHEMBL29773369 | 0.85 | L3MBTL1 (0.42) | DTYMKDDB1CRBNPOLBELANE | |
| SCHEMBL25703825 | 0.84 | POLB (0.41) | DTYMKDDB1CRBNPOLBELANE | |
| SCHEMBL3095175 | 0.82 | POLB (0.42) | DTYMKDDB1CRBNPOLBELANE | |
| SCHEMBL29587624 | 0.81 | POLB (0.41) | DTYMKDDB1CRBNPOLBELANE | |
| SCHEMBL2883080 | 0.81 | POLB (0.41) | DTYMKDDB1CRBNPOLBELANE | |
| SCHEMBL30991722 | 0.80 | POLB (0.40) | DTYMKDDB1CRBNPOLBELANE | |
| SCHEMBL155708 | 0.79 | MAP2K4 (0.44) | DTYMKELANEBRD4GABRG2GABRB3 | |
| SCHEMBL29626660 | 0.79 | MAP2K4 (0.44) | DTYMKELANEBRD4GABRG2GABRB3 | |
| SCHEMBL26911888 | 0.78 | DDB1 (0.45) | DTYMKDDB1CRBNPOLBGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113874363-B | Protein tyrosine phosphatase inhibitors | ARRAY生物制药公司 | 2024-11-12 | — | — | CN | disclosed |
| US-20240124453-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2024-04-18 | — | — | US | disclosed |
| US-11884664-B2 | Protein tyrosine phosphatase inhibitors | ARRAY BIOPHARMA INC. (US) | 2024-01-30 | — | — | US | disclosed |
| US-11634417-B2 | Protein tyrosine phosphatase inhibitors | ARRAY BIOPHARMA INC. (US) | 2023-04-25 | — | — | US | disclosed |
| US-20220251083-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2022-08-11 | — | — | US | disclosed |
| US-20200317665-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2020-10-08 | — | — | US | disclosed |
| US-10647675-B2 | Biaryl derivative and medicine containing same | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2020-05-12 | — | — | US | disclosed |
| US-10227342-B2 | Heteroaryl compounds for kinase inhibition | ARIAD PHARMACEUTICALS, INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-20190055199-A1 | BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2019-02-21 | — | — | US | disclosed |
| US-20170197962-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. | 2017-07-13 | — | — | US | disclosed |
| US-20170197962-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. | 2017-07-13 | — | — | US | disclosed |
| WO-2014041518-A1 | THIENOPYRROLE DERIVATIVES AS ITK INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2014-03-20 | — | — | WO | disclosed |
| US-7807684-B2 | HIV reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-10-05 | — | — | US | disclosed |
| EP-1912935-A2 | HIV REVERSE TRANSCRIPTASE INHIBITORS | Merck & Co., Inc. (US) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007015809-A2 | HIV REVERSE TRANSCRIPTASE INHIBITORS | MERCK & CO., INC. (US) | 2007-02-08 | — | — | WO | disclosed |
| US-20070021442-A1 | HIV reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197962-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ERBB2, EGFR, ERBB3 | DTYMK 350/4885DDB1 2297/4885CRBN 1030/4885 |
| US-11884664-B2 | Protein tyrosine phosphatase inhibitors | PPM1A, PPM1F, PPP5C | DTYMK 490/4885DDB1 1110/4885CRBN 1239/4885 |
| US-20200317665-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | PPM1A, PPM1F, PPP5C | DTYMK 490/4885DDB1 1110/4885CRBN 1239/4885 |
| US-10647675-B2 | Biaryl derivative and medicine containing same | MAN2B1, CBR3, MANBA | DTYMK 4033/4885DDB1 2731/4885CRBN 63/4885 |
| US-20190055199-A1 | BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME | MAN2B1, CBR3, MANBA | DTYMK 4033/4885DDB1 2731/4885CRBN 63/4885 |
| US-20070021442-A1 | HIV reverse transcriptase inhibitors | POLRMT, RNGTT, POLR2E | DTYMK 113/4885DDB1 2194/4885CRBN 4229/4885 |
| US-20240124453-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | PPM1A, PPM1F, PPP5C | DTYMK 490/4885DDB1 1110/4885CRBN 1239/4885 |
| US-10227342-B2 | Heteroaryl compounds for kinase inhibition | ERBB2, EGFR, ERBB3 | DTYMK 350/4885DDB1 2297/4885CRBN 1030/4885 |
| US-11634417-B2 | Protein tyrosine phosphatase inhibitors | PPM1A, PPM1F, PPP5C | DTYMK 490/4885DDB1 1110/4885CRBN 1239/4885 |
| US-20220251083-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | PPM1A, PPM1F, PPP5C | DTYMK 490/4885DDB1 1110/4885CRBN 1239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.